Dostarlimab: From preclinical investigation to drug approval and future directions

Immune checkpoint blockers (ICB) act by reverting the immunosuppressive phenotype of cancer cells, thus allowing host immune system to generate an immune response to the tumor. One of the key mechanisms targeted by ICB is the PD-1/PD-L1 axis, which lies onto the interaction between the programmed-ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Cicala, Carlo Maria, Musacchio, Lucia, Scambia, Giovanni, Lorusso, Domenica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Immunotherapy - Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026921/
https://www.ncbi.nlm.nih.gov/pubmed/36762991
http://dx.doi.org/10.1080/21645515.2023.2178220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026921/
https://www.ncbi.nlm.nih.gov/pubmed/36762991
http://dx.doi.org/10.1080/21645515.2023.2178220

Ejemplares similares